» Articles » PMID: 36180438

Household Transmission of SARS-CoV-2 Omicron Variant of Concern Subvariants BA.1 and BA.2 in Denmark

Abstract

SARS coronavirus 2 (SARS-CoV-2) continues to evolve and new variants emerge. Using nationwide Danish data, we estimate the transmission dynamics of SARS-CoV-2 Omicron subvariants BA.1 and BA.2 within households. Among 22,678 primary cases, we identified 17,319 secondary infections among 50,588 household contacts during a 1-7 day follow-up. The secondary attack rate (SAR) was 29% and 39% in households infected with Omicron BA.1 and BA.2, respectively. BA.2 was associated with increased susceptibility of infection for unvaccinated household contacts (Odds Ratio (OR) 1.99; 95%-CI 1.72-2.31), fully vaccinated contacts (OR 2.26; 95%-CI 1.95-2.62) and booster-vaccinated contacts (OR 2.65; 95%-CI 2.29-3.08), compared to BA.1. We also found increased infectiousness from unvaccinated primary cases infected with BA.2 compared to BA.1 (OR 2.47; 95%-CI 2.15-2.84), but not for fully vaccinated (OR 0.66; 95%-CI 0.57-0.78) or booster-vaccinated primary cases (OR 0.69; 95%-CI 0.59-0.82). Omicron BA.2 is inherently more transmissible than BA.1. Its immune-evasive properties also reduce the protective effect of vaccination against infection, but do not increase infectiousness of breakthrough infections from vaccinated individuals.

Citing Articles

Skin patch delivery of a SARS-CoV-2 spike DNA vaccine produces broad neutralising antibody responses.

McMillan C, Corner A, Wijesundara D, Choo J, Pittayakhajonwut D, Poredi I Heliyon. 2025; 11(4):e42533.

PMID: 40034315 PMC: 11872540. DOI: 10.1016/j.heliyon.2025.e42533.


Genomic Epidemiology of the Main SARS-CoV-2 Variants Circulating in Italy During the Omicron Era.

Bergna A, Lai A, Sagradi F, Menzo S, Mancini N, Bruzzone B J Med Virol. 2025; 97(2):e70215.

PMID: 39936851 PMC: 11816846. DOI: 10.1002/jmv.70215.


The changing demographics and severity in hospitalized patients across COVID-19 variants: A national cohort study.

Parajuli P, Phipps L, Sabo R, Alsaadawi R, Robinson A, French E J Clin Transl Sci. 2025; 9(1):e22.

PMID: 39911936 PMC: 11795861. DOI: 10.1017/cts.2024.1166.


SARS-CoV-2 evolution on a dynamic immune landscape.

Raharinirina N, Gubela N, Bornigen D, Smith M, Oh D, Budt M Nature. 2025; 639(8053):196-204.

PMID: 39880955 PMC: 11882442. DOI: 10.1038/s41586-024-08477-8.


Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era.

Cavalli M, Campoli G, Anselmo A, Brandi R, Fortunato A, Di Spirito M Sci Rep. 2025; 15(1):3372.

PMID: 39870695 PMC: 11772649. DOI: 10.1038/s41598-024-84952-6.


References
1.
Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y . SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct Target Ther. 2021; 6(1):430. PMC: 8678971. DOI: 10.1038/s41392-021-00852-5. View

2.
Bomze D, Sprecher E, Gamzu R . Effect of a nationwide booster vaccine rollout in Israel on SARS-CoV-2 infection and severe illness in young adults. Travel Med Infect Dis. 2021; 44:102195. PMC: 8556074. DOI: 10.1016/j.tmaid.2021.102195. View

3.
Li D, Li A, Li Z, Bao Y, Liu T, Qin X . SARS-CoV-2 Delta Variant in Jingmen City, Hubei Province, China, 2021: Children Susceptible and Vaccination Breakthrough Infection. Front Microbiol. 2022; 13:856757. PMC: 9043846. DOI: 10.3389/fmicb.2022.856757. View

4.
Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View

5.
Majumdar S, Sarkar R . Mutational and phylogenetic analyses of the two lineages of the Omicron variant. J Med Virol. 2021; 94(5):1777-1779. PMC: 9015627. DOI: 10.1002/jmv.27558. View